Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

The researchers hypothesized that these behaviors may alter concentrations of cardiac troponin, a marker of myocyte injury, and B-type natriuretic peptide, a marker of myocyte stress.

In 519 women with no evidence of cardiovascular disease, the researchers measured circulating concentrations of cardiac troponin T, using a high-sensitivity assay (hsTnT), and the N-terminal fragment of B-type natriuretic peptide (NT-proBNP).

Who Took Part

According to the abstract, 519 women were involved.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

In 519 women with no evidence of cardiovascular disease, the researchers measured circulating concentrations of cardiac troponin T, using a high-sensitivity assay (hsTnT), and the N-terminal fragment of B-type natriuretic peptide (NT-proBNP).

PubMed files the paper under topics including Aspirin, Biomarkers, Cardiovascular Diseases, Incidence, Massachusetts, Myocardium and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized and double-blind study of BNP (Nesiritide) in 519 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2016 (The American journal of cardiology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.